In-situ TiO <sub>2-x</sub> decoration of titanium carbide MXene for photo/sono-responsive antitumor theranostics

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Sonodynamic therapy (SDT) has emerged as a noninvasive therapeutic modality that involves sonosensitizers and low-intensity ultrasound. However, owing to the rapid recombination of charge carriers, most of the sonosensitizers triggered poor reactive oxygen species (ROS) generation, resulting in unsatisfactory sonodynamic therapeutic effects.

Results

Herein, a photo/sono-responsive nanoplatform was developed through the in-situ systhesis of TiO _2-x on the surface of two-dimensional MXene (titanium carbide, Ti ₃C ₂) for photoacoustic/photothermal bimodal imaging-guided near-infrared II (NIR-II) photothermal enhanced SDT of tumor. Because of several oxygen vacancies and smaller size (~ 10 nm), the in-situ formed TiO _2-x nanoparticles possessed narrow band gap (2.65 eV) and high surface area, and thus served as a charge trap to restrict charge recombination under ultrasound (US) activation, resulting in enhanced sonodynamic ROS generation. Moreover, Ti ₃C ₂ nanosheets induced extensive localized hyperthermia relieves tumor hypoxia by accelerating intratumoral blood flow and tumor oxygenation, and thus further strengthened the efficacy of SDT. Upon US/NIR-II laser dual-stimuli, Ti ₃C ₂@TiO _2-x nanoplatform triggered substantial cellular killing in vitro and complete tumor eradication in vivo, without any tumor recurrence and systemic toxicity.

Conclusion

Our work presents the promising design of photo/sono-responsive nanoplatform for cancer nanotheranostics.

Graphical Abstract

Supplementary Information

The online version contains supplementary material available at 10.1186/s12951-022-01253-8.

Related collections

Most cited references 56

Record: found
Abstract: found
Article: not found

Cancer treatment and survivorship statistics, 2019

Kimberly D Miller, Leticia Nogueira, Angela Mariotto … (2019)

The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Data Base are presented for the most prevalent cancer types. Cancer-related and treatment-related short-term, long-term, and late health effects are also briefly described. More than 16.9 million Americans (8.1 million males and 8.8 million females) with a history of cancer were alive on January 1, 2019; this number is projected to reach more than 22.1 million by January 1, 2030 based on the growth and aging of the population alone. The 3 most prevalent cancers in 2019 are prostate (3,650,030), colon and rectum (776,120), and melanoma of the skin (684,470) among males, and breast (3,861,520), uterine corpus (807,860), and colon and rectum (768,650) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost two-thirds (64%) are aged 65 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by follow-up care providers. Although there are growing numbers of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care.

0 comments Cited 1777 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.

Jung Suk, Qingguo Xu, Namho Kim … (2016)

Coating the surface of nanoparticles with polyethylene glycol (PEG), or "PEGylation", is a commonly used approach for improving the efficiency of drug and gene delivery to target cells and tissues. Building from the success of PEGylating proteins to improve systemic circulation time and decrease immunogenicity, the impact of PEG coatings on the fate of systemically administered nanoparticle formulations has, and continues to be, widely studied. PEG coatings on nanoparticles shield the surface from aggregation, opsonization, and phagocytosis, prolonging systemic circulation time. Here, we briefly describe the history of the development of PEGylated nanoparticle formulations for systemic administration, including how factors such as PEG molecular weight, PEG surface density, nanoparticle core properties, and repeated administration impact circulation time. A less frequently discussed topic, we then describe how PEG coatings on nanoparticles have also been utilized for overcoming various biological barriers to efficient drug and gene delivery associated with other modes of administration, ranging from gastrointestinal to ocular. Finally, we describe both methods for PEGylating nanoparticles and methods for characterizing PEG surface density, a key factor in the effectiveness of the PEG surface coating for improving drug and gene delivery.

0 comments Cited 950 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

A view on drug resistance in cancer

Neil Vasan, José Baselga, David M Hyman (2019)

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

0 comments Cited 888 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Peng Huang:

ORCID: http://orcid.org/0000-0003-3651-7813

peng.huang@szu.edu.cn

Jing Lin: jingl@szu.edu.cn

Journal

Journal ID (nlm-ta): J Nanobiotechnology

Journal ID (iso-abbrev): J Nanobiotechnology

Title: Journal of Nanobiotechnology

Publisher: BioMed Central (London )

ISSN (Electronic): 1477-3155

Publication date (Electronic): 28 January 2022

Publication date PMC-release: 28 January 2022

Publication date Collection: 2022

Volume: 20

Electronic Location Identifier: 53

Affiliations

[1 ]GRID grid.414906.e, ISNI 0000 0004 1808 0918, Department of Hepatobiliary Surgery, , The First Affiliated Hospital of Wenzhou Medical University Wenzhou, ; Zhejiang, 325000 China

[2 ]GRID grid.508211.f, ISNI 0000 0004 6004 3854, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, , Marshall Laboratory of Biomedical Engineering, Shenzhen University Health Science Center, ; Shenzhen, 518060 China

Author information

Peng Huang http://orcid.org/0000-0003-3651-7813

Article

Publisher ID: 1253

DOI: 10.1186/s12951-022-01253-8

PMC ID: 8796495

PubMed ID: 35090484

SO-VID: 66429b75-1b73-45d8-83d0-477ac261e987

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 30 October 2021

Date accepted : 9 January 2022

Funding

Funded by: Basic Research Program of Shenzhen

Award ID: JCYJ20200109105620482

Award Recipient : Jing Lin

Funded by: Basic Research Program of Shenzhen

Award ID: JCYJ20180507182413022

Award Recipient : Peng Huang

Custom metadata

ScienceOpen disciplines: Biotechnology

Keywords: titanium carbide,oxygen deficient titanium dioxide,photoacoustic imaging,photothermal therapy,sonodynamic therapy

Data availability:

ScienceOpen disciplines: Biotechnology

Keywords: titanium carbide, oxygen deficient titanium dioxide, photoacoustic imaging, photothermal therapy, sonodynamic therapy

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 27

See all cited by

Most referenced authors 1,288

See all reference authors